Forecast
Period
|
2026-2030
|
Market
Size (2024)
|
USD
2.62 Billion
|
CAGR
(2025-2030)
|
4.33%
|
Fastest
Growing Segment
|
Papillary
Carcinoma
|
Largest
Market
|
North
America
|
Market
Size (2030)
|
USD
3.34 Billion
|
Market Overview
Global Thyroid Cancer Diagnostics Market was valued at USD 2.62 Billion in 2024 and is expected to reach USD 3.34 Billion by 2030 with a CAGR of 4.33% during the forecast period. The global thyroid cancer diagnostics market is a dynamic
and rapidly evolving segment of the healthcare industry. Thyroid cancer, a
malignancy that affects the thyroid gland, has been on the rise in recent
years, making early and accurate diagnosis essential for effective treatment.
The market for thyroid cancer diagnostics encompasses various diagnostic
techniques and tools that aid in the detection, evaluation, and monitoring of
this form of cancer.
Key Market Drivers
Rising Incidence Rates
Thyroid
cancer, a malignancy of the thyroid gland, is on the rise globally, posing a
growing health challenge. While the exact reasons behind this trend are not
fully understood, the escalating incidence of thyroid cancer is undeniably a
driving force behind the growth of the global thyroid cancer diagnostics
market.
Environmental
factors, including exposure to radiation and certain chemicals, are believed to
play a role in the development of thyroid cancer. Radioactive iodine, a
byproduct of nuclear accidents, and certain industrial chemicals have been
linked to an increased risk. Changes in lifestyle, including dietary habits and
obesity, may influence the development of thyroid cancer. These lifestyle
factors are more prevalent in contemporary society, potentially contributing to
the rising incidence. Previous exposure to therapeutic or diagnostic radiation,
especially in the form of head and neck radiation therapy during childhood, is
a well-established risk factor for thyroid cancer. Advances in medical imaging
and diagnostic technologies have led to earlier and more accurate detection of
thyroid cancer. This has uncovered previously undiagnosed cases and contributed
to the rising incidence.
According to the American Cancer Society, it is estimated that in 2025, the United States will see approximately 44,020 new cases of thyroid cancer, with 12,670 cases in men and 31,350 in women, along with an expected 2,290 deaths from the disease, including 1,090 men and 1,200 women. These rising incidence rates not only underscore the increasing burden of thyroid cancer but also drive the growing demand for advanced diagnostic solutions. As the number of cases continues to rise, the global thyroid cancer diagnostics market is expected to experience significant growth, with a greater focus on early detection technologies and improved treatment options to address the evolving healthcare needs. As
the number of thyroid cancer cases continues to climb, the demand for
diagnostic tools escalates accordingly. The market responds by offering a wide
range of diagnostic techniques and technologies to assist in the detection,
evaluation, and monitoring of thyroid cancer. These tools include ultrasound,
fine-needle aspiration biopsy, molecular diagnostics, nuclear imaging, and
blood tests, among others. The upward trajectory of thyroid cancer incidence
encourages continuous investment in research and development by both private
and public sectors. This investment leads to innovations in diagnostic methods,
with a focus on improving accuracy and early detection. Consequently, new and
improved diagnostic technologies are brought to the market, further stimulating
its growth. The growing awareness of thyroid cancer's prevalence and risk
factors leads to more individuals seeking regular check-ups and diagnostic
tests. This results in earlier detection of thyroid cancer cases, which is
essential for effective treatment and improved patient outcomes. Screening
programs, often targeted at high-risk populations, have become more common,
boosting diagnostic market growth. The rising incidence of thyroid cancer is
not uniform across the globe. Some regions, such as North America and Europe,
exhibit higher rates of thyroid cancer compared to others. These disparities
create varying demands for diagnostic tools, with markets in regions with
higher incidence experiencing more significant growth. Governments and
healthcare systems are prompted to allocate resources to cope with the rising
incidence of thyroid cancer. This includes investments in healthcare
infrastructure and technology, facilitating greater access to advanced
diagnostic procedures and treatments, thus supporting market expansion.
Technological Advancements
Technological
advancements have played a pivotal role in revolutionizing the landscape of
healthcare, particularly in the realm of diagnostics. The global thyroid cancer
diagnostics market is no exception, benefiting significantly from innovations
that have led to more accurate, efficient, and minimally invasive diagnostic
techniques.
The
field of thyroid cancer diagnostics has experienced a paradigm shift over the
past few decades, thanks to rapid technological advancements. Traditional
diagnostic methods have given way to more sophisticated and precise approaches,
which have had a profound impact on the management and treatment of thyroid
cancer.
One
of the most significant technological advancements in thyroid cancer
diagnostics has been the refinement of imaging techniques, such as ultrasound.
High-resolution ultrasound technology allows healthcare professionals to
visualize the thyroid gland in exquisite detail. This not only aids in the
detection of nodules but also assists in characterizing them, differentiating
between benign and malignant growths.
Molecular
diagnostics have emerged as a game-changer in thyroid cancer management. The
identification of specific genetic mutations and biomarkers associated with
thyroid cancer allows for a more precise diagnosis. Tests that analyze the
presence of mutations in genes like BRAF, RET/PTC, and RAS provide valuable
information, guiding treatment decisions and prognosis.
Fine-needle
aspiration biopsy is a minimally invasive procedure that has gained prominence
due to technological improvements. Ultrasound guidance and better needle design
have made FNAB more accurate and less discomforting for patients. This
procedure is instrumental in obtaining tissue samples for histopathological
examination, ultimately confirming or ruling out thyroid cancer.
Nuclear
imaging techniques, particularly the use of radioactive iodine, have become
more precise and safer. Radioactive iodine is employed in diagnosing and
treating thyroid cancer. Improved imaging systems and refinements in the
administration of radioactive iodine have enhanced the accuracy and safety of
this diagnostic method.
The
digital revolution in healthcare is playing an increasingly important role in
thyroid cancer diagnostics. Telemedicine allows for remote consultations and
the sharing of medical records, images, and test results. This enables timely
assessments and consultations with specialists, making it easier for patients
in remote or underserved areas to access advanced diagnostic tools.
AI-powered
diagnostic tools are emerging as a significant advancement in the field.
Machine learning algorithms can analyze medical images and data more rapidly
and accurately than humans, assisting healthcare professionals in detecting
abnormalities and making more precise diagnoses. This not only saves time but
also enhances the accuracy of thyroid cancer diagnostics.
Advanced
technologies have significantly improved the accuracy of thyroid cancer
diagnosis, reduced the chances of misdiagnosis or missed cases. Less invasive
diagnostic techniques, like FNAB, have led to higher patient acceptance and
compliance, further encouraging early diagnosis. Improved diagnostic tools
facilitate earlier detection of thyroid cancer, leading to timelier and more
effective treatment, which, in turn, positively impacts patient outcomes. The
continuous quest for improved diagnostic technologies has resulted in
substantial research and development investment by both public and private
sectors. This investment drives innovation and the introduction of new
diagnostic solutions.
Increased Healthcare Spending
Healthcare
spending is a critical factor in the growth and development of medical
technologies and services. The global thyroid cancer diagnostics market is no
exception to this rule. The ever-increasing investment in healthcare
infrastructure, research, and diagnostic technologies is propelling the
expansion of the thyroid cancer diagnostics market, with a focus on early
detection, accurate diagnosis, and improved patient outcomes.
Thyroid
cancer, a malignancy affecting the thyroid gland, has been on the rise in
recent years, making it an increasingly significant health concern worldwide.
While the exact reasons behind the increase in incidence are still under
investigation, the rising number of thyroid cancer cases is prompting
healthcare systems to allocate more resources to address this challenge. According to the American Cancer Society, the cost of cancer-related healthcare in the U.S. is expected to reach USD 222 billion by 2025, a 21% increase from USD 183 billion in 2015. Furthermore, the American Society of Clinical Oncology highlights that radiation therapy costs can range from USD 8,600 to USD 25,500 per treatment course, depending on the specifics of the treatment. This significant rise in healthcare spending is contributing to the growing demand for more efficient and cost-effective diagnostic solutions in the global thyroid cancer diagnostics market. As healthcare expenditures continue to rise, there is an increasing emphasis on early detection technologies that can reduce long-term treatment costs and improve patient outcomes, further fueling market expansion.
A
significant portion of increased healthcare spending goes towards research and
development, which is crucial for the advancement of diagnostic technologies.
These investments result in the development of cutting-edge diagnostic tools
and techniques, making early detection and accurate diagnosis of thyroid cancer
possible. Increased healthcare spending translates into better healthcare
infrastructure. Patients now have access to state-of-the-art diagnostic
facilities, equipped with the latest technologies that enhance the accuracy and
efficiency of thyroid cancer diagnosis. This fosters a more favorable
environment for growth in the thyroid cancer diagnostics market. Healthcare
systems with higher budgets often implement population-based screening
programs, which are critical for detecting thyroid cancer at an early stage.
These screening programs specifically target high-risk populations or areas
with a history of thyroid cancer prevalence. The availability of resources and
funding is essential for the successful implementation and continuation of
these programs. Increased healthcare spending allows for the training and
education of healthcare professionals, ensuring they are well-versed in the
latest diagnostic techniques and can effectively utilize advanced technologies
for thyroid cancer diagnosis. Higher healthcare budgets not only affect
diagnostic capabilities but also improve the overall management of thyroid
cancer. This includes access to innovative therapies and treatment options,
which further emphasizes the importance of accurate diagnosis for personalized
treatment plans. Healthcare systems with more resources can invest in patient
awareness campaigns, educating the public about the importance of regular
check-ups and early detection of thyroid cancer. As awareness increases, more
patients seek diagnostic evaluations, driving the demand for thyroid cancer
diagnostics.
Geographic Variation
Geographic
variation in the prevalence of diseases is a well-recognized phenomenon in the
field of medicine. The global thyroid cancer diagnostics market, which
encompasses diagnostic tools and techniques for detecting thyroid cancer, is
significantly influenced by regional disparities in the incidence of the
disease.
Certain
areas, such as parts of the United States and Eastern Asia, have shown higher
incidences of thyroid cancer. Factors like genetics, iodine intake, and
environmental conditions can contribute to these regional hotspots. Low-income
regions often have limited access to healthcare facilities and advanced
diagnostic technologies. This can result in delayed diagnosis and treatment,
impacting the overall prevalence of thyroid cancer in these areas. Areas with
higher exposure to radiation or certain environmental pollutants may experience
increased rates of thyroid cancer. For instance, regions affected by nuclear
accidents may see a surge in thyroid cancer cases. Genetic factors can influence
the development of thyroid cancer. Some regions may have a higher prevalence of
genetic mutations associated with this cancer, contributing to regional
variations.
Regions
with a higher incidence of thyroid cancer naturally create a greater demand for
diagnostic tools. This includes ultrasound, fine-needle aspiration biopsy,
molecular diagnostics, and other diagnostic techniques to facilitate early
detection and diagnosis. Healthcare systems and research institutions in
regions with higher prevalence often channel their efforts into understanding
the disease and improving diagnostic capabilities. This leads to advancements
in diagnostic technologies that can benefit the global market. Due to the
increased demand for thyroid cancer diagnostics in these regions, the market
experiences robust growth. Companies specializing in diagnostic tools focus on
serving these high-incidence areas, which can stimulate market expansion. Regions
with high thyroid cancer incidence often invest in healthcare infrastructure to
cope with the burden of the disease. This may include setting up specialized
thyroid cancer clinics and research centers, further contributing to market
growth. In areas with higher incidence rates, there's typically a heightened
awareness of thyroid cancer. Public health initiatives and awareness campaigns
are more likely to be in place, encouraging individuals to seek diagnostic
evaluations and fostering market growth. Regions with a higher prevalence of
thyroid cancer are more likely to have access to innovative therapies and
treatment options. Accurate diagnostics are crucial in guiding personalized
treatment plans, making diagnostic tools a central aspect of comprehensive
thyroid cancer care.

Download Free Sample Report
Key Market Challenges
False-Positive Results
One
of the primary challenges in thyroid cancer diagnostics is the occurrence of
false-positive results. Thyroid nodules are relatively common, and many of them
are benign. Diagnostic tests such as ultrasound and fine-needle aspiration
biopsy (FNAB) may sometimes suggest malignancy when, in fact, the nodule is
non-cancerous. False positives can lead to unnecessary anxiety for patients,
additional testing, and potentially invasive procedures.
Overdiagnosis and
Overtreatment
Overdiagnosis,
the identification of cancers that would never cause symptoms or harm during a
patient's lifetime, is a significant concern. In thyroid cancer, overdiagnosis
often leads to overtreatment, which involves the removal of the thyroid gland
or radioactive iodine treatment that may not be necessary. Overdiagnosis can
result in unnecessary costs and potential harm to patients.
Limited Access in Low-Income
Regions
Access
to advanced diagnostic tools and healthcare services is not uniform across the
globe. Low-income regions often lack the infrastructure and resources necessary
for early diagnosis and effective management of thyroid cancer. This disparity
can lead to delayed diagnosis and poorer outcomes in these areas.
Key Market Trends
Molecular Diagnostics and
Genetic Testing
Molecular
diagnostics have revolutionized the field of cancer diagnosis, and thyroid
cancer is no exception. The trend toward molecular diagnostics and genetic
testing is gaining momentum. In May 2024, Foundation Medicine, Inc. launched FoundationOne RNA in the U.S., a tissue-based RNA sequencing test that detects cancer-related gene fusions across 318 genes. This test is particularly valuable for identifying fusions in solid tumors, including thyroid cancer, as well as other cancers like non-small cell lung cancer (NSCLC), pancreatic cancer, and sarcoma. Initially available for research use since September 2023, the test is now being introduced for clinical applications. This innovation directly impacts the thyroid cancer diagnostics market, aligning with the growing trend of molecular diagnostics and genetic testing. As these advanced technologies enable more precise and personalized approaches to diagnosing and treating thyroid cancer, the demand for such diagnostic tools is expected to drive significant growth in the market. Specific genetic mutations and alterations
associated with thyroid cancer are now being used to inform diagnosis and
treatment decisions. This trend not only allows for more precise diagnosis but
also opens the door to personalized treatment plans tailored to the genetic
profile of the patient's tumor.
Liquid Biopsies
Liquid
biopsies are a non-invasive and promising trend in thyroid cancer diagnostics.
These tests analyze blood samples for circulating tumor DNA, RNA, or other
molecules to detect cancer-related genetic mutations or alterations. Liquid
biopsies are less invasive than traditional tissue biopsies and can potentially
allow for the monitoring of thyroid cancer without repeated invasive
procedures.
Growth of Remote Screening
Programs
Population-based
screening programs for thyroid cancer are growing in prominence. These programs
are particularly focused on high-risk populations and areas with a history of
thyroid cancer prevalence. The development of remote screening programs allows for
more efficient and accessible thyroid cancer screening and early detection.
Segmental Insights
Type Insights
Based on Type, the Papillary Carcinoma emerged as the fastest growing segment in the global market for Thyroid Cancer Diagnostics during the forecast period. Papillary thyroid carcinoma (PTC) is the most prevalent form of thyroid cancer, representing approximately 80-85% of all cases. The rising number of diagnoses, especially among women, has driven greater demand for diagnostic testing. Advances in imaging, molecular diagnostics, and genetic testing have facilitated the earlier detection of papillary carcinoma, enabling more effective treatment options and motivating patients to pursue diagnosis and care. Increased awareness of thyroid cancer, including PTC, fueled by educational initiatives and improved healthcare access, has led to more people seeking screenings, further boosting market growth. The introduction of non-invasive diagnostic methods, such as fine-needle aspiration (FNA) and genetic testing has made PTC diagnosis more accessible and cost-effective, particularly in regions with developing healthcare infrastructure. These factors, along with the overall rise in thyroid cancer diagnoses, position the Papillary Carcinoma segment as the fastest growing in the thyroid cancer diagnostics market.
Technique Insights
Based on Technique, imaging emerged as the dominating segment in the global market for Thyroid Cancer Diagnostics in 2024. Imaging
examinations continue to play a central role in thyroid cancer for disease
detection and staging. Diagnostic tools like neck ultrasounds or CT/MRI scans
are highly recommended for identifying the disease. Additional imaging
procedures such as chest X-rays, bone scans, PET scans, and radioiodine scans
are employed to determine the stage of cancer and locate metastases. This
segment's revenue is primarily driven by technological advancements and the
relatively higher costs associated with these diagnostic procedures within the
thyroid cancer diagnostics market. Thyroid
ultrasound assessments are used to assess structural irregularities, while
blood tests, measuring TSH, T4, and T3 levels, provide insights into functional
aspects. Fine needle biopsy is employed in cases where there is suspicion of
malignancy to determine the nature of the tumor, whether it is benign or
malignant. Furthermore, the landscape of thyroid cancer diagnostics is evolving
with the introduction of molecular testing and genetic prognosis, contributing
to advancements in this market.

Download Free Sample Report
Regional Insights
Based on Region, North America emerged as the dominant region in the Global Thyroid Cancer Diagnostics Market in 2024. North America, particularly the United States, has a relatively high incidence of thyroid cancer, especially papillary thyroid carcinoma, which contributes significantly to the demand for advanced diagnostic solutions. According to the American Cancer Society, while the number of thyroid cancer diagnoses continues to rise, the stricter diagnostic criteria introduced since 2014 have led to a 2% annual decline in the incidence rate. Despite this decline, thyroid cancer is still diagnosed at a younger age compared to other adult cancers, with the average diagnosis age being 51, further driving the need for effective diagnostic tools in the region. The region benefits from advanced healthcare infrastructure, enabling the adoption of cutting-edge diagnostic technologies like molecular diagnostics, imaging techniques, and genetic testing, which enhance early detection and treatment outcomes. North America is also home to prominent pharmaceutical companies, medical research institutions, and diagnostic technology developers, which invest significantly in innovative thyroid cancer diagnostic solutions. This investment has resulted in major advancements in the accuracy and efficiency of detection. With some of the highest healthcare spending globally, North America supports the development and widespread use of these advanced tools, ensuring broader access to diagnostic services and improved patient care. Additionally, the availability of health insurance, particularly in the U.S., facilitates access to comprehensive diagnostic testing, further promoting the use of advanced technologies and contributing to market growth.
Recent Developments
- In
October 2024, the Indian Institute of Technology, Indore (IIT-I), developed an
affordable and compact cancer screening device utilizing photoacoustic
technology. This device is designed to enable early-stage detection of cancers,
such as thyroid cancer, in patients. It is expected to lower diagnostic costs
to about one-tenth of traditional methods and can be easily transported for
screenings in rural and remote areas with limited healthcare infrastructure.
- In
October 2024, UCLA and the Parker Institute for Cancer Immunotherapy (PICI)
renewed their partnership to advance cancer immunotherapy research and develop
curative treatments for hard-to-treat cancers. PICI has committed USD 125
million to support research across a consortium of immuno-oncology academic
institutions. Through this collaboration, UCLA has launched one of the first
multi-site clinical trials using CAR T-cell therapy to target IL13Ra2, a
protein commonly found in melanoma, certain thyroid cancers, and rare tumors
like neuroendocrine tumors, adrenocortical carcinoma, paraganglioma, and
pheochromocytoma.
- In
September 2024, scientists at Harvard Medical School, led by Dr. Kun-Hsing Yu,
developed a versatile AI model, Clinical Histopathology Imaging Evaluation
Foundation (CHIEF), capable of diagnosing multiple cancer types. Unlike current
AI methods, CHIEF enhances diagnostic accuracy and efficiency, helping
clinicians identify patients who may not respond to standard treatments.
Trained on 15 million unlabeled tile images and further refined with 60,000
whole-slide tissue images from cancers such as lung, breast, prostate, thyroid,
and pancreatic, CHIEF demonstrates the growing potential of AI in cancer
diagnosis.
- In
July 2024, Optime Care, a leading specialty pharmacy and part of AscellaHealth,
entered into a partnership with Rigel Pharmaceuticals, Inc. to offer a full
range of services supporting patients using GAVRETO (pralsetinib). GAVRETO is
an oral targeted therapy prescribed for certain cancers caused by abnormal RET
genes, including advanced thyroid cancer or metastatic thyroid cancer in
patients aged 12 and older who have not responded to or no longer respond to
radioactive iodine treatment.
Key Market Players
- F
Hoffmann-La Roche AG
- Abbott Laboratories Inc
- Thermo Fisher Scientific Inc
- General Electric Co
- Siemens Healthcare GmbH
- Bio-Rad Laboratories Inc
- Toshiba Corporation
- Koninklijke Philips NV
- Agilent Technologies Inc
By
Type
|
By
Technique
|
By
End-use
|
By
Region
|
- Papillary
Carcinoma
- Follicular
Carcinoma
- Others
|
- Blood
Test
- Imaging
- Biopsy
- Others
|
- Hospital
Laboratories
- Cancer
Diagnostic Centers
- Research
Institutes
- Others
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Thyroid Cancer
Diagnostics Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Thyroid Cancer Diagnostics Market, By Type:
o Papillary Carcinoma
o Follicular Carcinoma
o Others
- Thyroid Cancer Diagnostics Market, By Technique:
o Blood Test
o Imaging
o Biopsy
o Others
- Thyroid Cancer Diagnostics Market, By End-use:
o Hospital Laboratories
o Cancer Diagnostic Centers
o Research Institutes, Others
- Thyroid Cancer Diagnostics Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Thyroid
Cancer Diagnostics Market.
Available Customizations:
Global Thyroid Cancer Diagnostics market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Thyroid Cancer Diagnostics Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]